Hefei Afana Biotechnology Co., Ltd.

Main purpose: PART1: Dose escalation phase To evaluate the safety and tolerability of this product in patients with HPV16 and/or HPV18-related high-grade cervical squamous intraepithelial lesions [HSIL], and explore the maximum tolerated dose (MTD). PART2: Case expansion phase To evaluate the safety, tolerability and preliminary efficacy of this product in patients with HPV16 and/or HPV18-related high-grade cervical squamous intraepithelial lesions [HSIL], and determine the recommended dose (RP2D) for Phase II clinical trials. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of this product in patients with HPV16 and/or HPV18-related high-grade cervical squamous intraepithelial lesions [HSIL]. To evaluate the immunogenicity of this product in patients with HPV16 and/or HPV18-related high-grade cervical squamous intraepithelial lesions [HSIL]. To evaluate the pharmacodynamic (PD) characteristics of this product in patients with HPV16 and/or HPV18-related high-grade cervical squamous intraepithelial lesions [HSIL]: the level of cellular immune response and the CD4+ and CD8+ T lymphocyte responses induced. Exploratory purpose: To evaluate the pharmacodynamic (PD) characteristics of this product in patients with HPV16 and/or HPV18-related high-grade cervical squamous intraepithelial lesions [HSIL]: changes in serum cytokines (IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-6, IL-10 and IL-17A).

1. Primary purpose To evaluate the safety and tolerability of one dose of RSV mRNA vaccine in people aged 18 years and above. 2. Secondary purpose 1) To preliminarily evaluate the immunogenicity of one dose of RSV mRNA vaccine at different time points in people aged 18 years and above. 2) To explore the immune persistence of people aged 18 years and above after one dose of RSV mRNA vaccine.